- Jul 2018
-
europepmc.org europepmc.org
-
On 2014 Feb 25, Krishnaswamy Sampathkumar commented:
This paper resurrects Atenolol back to clinical use. The author has always been a protagonist of use of atenolol in hemodialysis due to its prolonged half life in anuric patients and ease of administration. It outscores ACE inhibitors in many cv adverse events. I will be interested in knowing about the stroke outcomes as atenolol is blamed for increasing the CVA risk as in LIFE trial.
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-
- Feb 2018
-
europepmc.org europepmc.org
-
On 2014 Feb 25, Krishnaswamy Sampathkumar commented:
This paper resurrects Atenolol back to clinical use. The author has always been a protagonist of use of atenolol in hemodialysis due to its prolonged half life in anuric patients and ease of administration. It outscores ACE inhibitors in many cv adverse events. I will be interested in knowing about the stroke outcomes as atenolol is blamed for increasing the CVA risk as in LIFE trial.
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-